House · HR 8205 · 119th Congress
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Summary
This bill extends federal funding and programs for ALS research through 2031. It covers grants from the NIH and FDA to develop treatments for ALS and other rare brain diseases. Researchers and patients with ALS and similar conditions are the main groups affected.
In Favor
Without this bill, the legal authority behind ALS research and patient support programs expires in 2026. Reauthorization keeps that framework in place so Congress can fund these programs if it chooses to. Letting authority lapse would force a full restart, delaying help for patients with a disease that still has no cure.
Against
This bill extends programs without guaranteeing new money to fund them. Congress expresses support for direct funding but does not require it. If money is not actually set aside, the extended programs may exist on paper but still lack the resources to help patients.
Additional Considerations
Purpose & Problem
Is the problem real and worth federal action?
This bill extends a federal program that funds research on treatments for ALS, a fatal nerve disease, and other rare brain diseases through 2031. The original program was set to end in 2026.
Scope & Related Provisions
Does it stay focused, or carry unrelated add-ons?
The bill stays focused on ALS and related rare brain diseases. It adds reporting duties for the FDA and a review by the Government Accountability Office, both tied to the same research program.
Who Is Affected
Who benefits, and who bears the cost?
People with ALS and related rare brain diseases may be affected as research funding continues. Drug makers seeking grant renewals must share trial data with the FDA, adding a new duty for them.
Cost & Funding
Is it affordable and responsibly funded?
The bill reauthorizes grants through NIH and FDA but does not state a specific dollar amount. Congress expresses support for directly funding each part of the program, but no appropriation is included in this bill's text.
Risks & Implementation
What could go wrong in practice?
The FDA must publish an updated action plan within one year, which requires staff time and coordination across agencies. Drug makers must share early trial data, and how quickly they can do so may affect the grant review process.
For the actual bill text, see congress.gov.
AI-generated · Published 7/23/2026